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Introduction 
Bothrops atrox (Viperidae), the common lancehead, is a ter-
restrial, generally nocturnal and highly adaptable pit viper 
found in tropical lowlands and rainforest (Campbell & La-
mar 2004). Poisoning by B. atrox, as with other species, trig-
gers local and systemic effects in victims (Borges et al. 1999). 
This species is responsible for most snakebites in the Ama-
zon rainforest region, where difficulties in access to health-
care might increase accident severity. 
Bothropic envenoming induces prominent local lesions 
that are caused by the combined action of venom prote-
ases, haemorrhagic factors, phospholipases A2 (PLA2) and 
from the release of endogenous mediators (Rothschild & 
Rothschild 1979; Gutiérrez & Lomonte 1989; Trebien & Ca-
lixto 1989; Farsky et al. 1997; Carneiro et al. 2002; Laing et 
al. 2003; Teixeira et al. 2003). Adequate treatment of snake-
bite envenoming depends on the ability of antivenoms to re-
verse systemic signs, such as venom-induced coagulopathy, 
haemorrhage, hypotensive shock, among others (Calvete et 
al. 2009; Núñez et al. 2009). Animal models and clinical stud-
ies have demonstrated that local reactions are not effectively 
neutralized by conventional antivenom serum therapy (Avila-
Agüero et al. 2001; Lomonte et al. 2009). In severe cases, 
local effects of envenoming may lead to permanent tissue 
loss, disability or amputation (Gutiérrez 2002). Such adverse 
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Abstract 
Context: Medicinal plants encompass a rich source of active compounds that can neutralize snake venoms or toxins. Costus spicatus (Jacq.) Sw. (Costa-
ceae) is used by the Amazonian population to treat inflammation, pain and other pathological manifestations. 
Objective: To evaluate the influence of C. spicatus aqueous extract on edema, peritonitis, nociception, coagulation, haemorrhage and indirect hae-
molytic activity induced by Bothrops atrox venom (BAV). 
Materials and methods: Dried and pulverized leaves were extracted with distilled water. Envenoming was induced by administration of B. atrox 
snake venom in Swiss Webster mice. The experimental groups consisted of BAV (at the minimum dose to induce measurable biological re-
sponses) and C. spicatus extract (CSE, 1.25, 2.5, 5.0, 7.5 and 10 mg/kg/25 ml phosphate-buffered saline) administered individually and in combi-
nation (BAVCSE). PBS was used as a control. In vitro assays were also conducted in order to evaluate phospholipase A2 coagulant activities (in-
direct haemolytic method). 
Results: CSE significantly reduced the venom-induced edema and nociception at all concentrations tested and inhibited migration of inflammatory 
cells at the three least concentrations (5.0, 7.5 and 10 mg/kg/25 ml PBS). CSE was not effective in inhibiting coagulant, haemorrhagic and in-
direct haemolytic activities of the venom. 
Discussion and conclusion: The data suggest that CSE could exhibit a central mechanism for pain inhibition, and may also inhibit prostaglandin 
synthesis. These findings corroborate the traditional administration of C. spicatus decoction to treat inflammatory disorders, including those 
caused by B. atrox envenomation. 
Keywords: Medicinal plants, snakebites, toxins
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complications can be controlled by use of anti-inflammatory 
remedies concomitant with antivenom to reduce local pain 
and inflammation. 
Use of medicinal plants has been an elected practice 
throughout human history, whose knowledge, gathered 
through the experience of many generations, represents 
millennia of popular wisdom, since the times when the only 
available medicinal resources were obtained from the veg-
etal kingdom (Calixto et al. 2000). Medicinal plants still play 
a key role in world health as they are a rich source of many 
natural inhibitors and pharmacologically active compounds. 
Many of these substances structurally resemble biological 
compounds, and this similarity is the basis of their physiolog-
ical action (Havsteen 1983). Some medicinal plants are used 
in the Amazon and elsewhere against snakebites or as anti-
inflammatory agents, and these plants may prove valuable 
adjuvants to antivenom therapies (da Silva et al. 2005; Soares 
et al. 2005; Bittencourt et al. 2014). Hence, it is crucial to un-
dertake an in-depth scientific investigation on the pharma-
cological and toxicological actions of these plants. 
Costus spicatus Swartz (Costaceae), commonly called 
‘cana-do-brejo’, ‘canafístula’ or ‘canarana’ in Brazil, is a me-
dicinal plant found in wet coastal forests (Silva 2002; da Silva 
& Parente 2003). Ethnopharmacological surveys have es-
tablished that C. spicatus leaf and stem decoctions as well 
as aqueous or alcoholic infusions are commonly used for 
the treatment of renal calculi, cutaneous ulcers, infections, 
inflammation, urethritis, gonorrhea and leucorrhoea (Car-
riconde et al. 1996; Araújo Viel et al. 1999; da Silva et al. 
2000; Silva 2002). Studies have reported the isolation and 
chemical characterization of three neutral polysaccharides 
with anti-inflammatory and immunomodulatory activities 
(da Silva & Parente 2003). Other work has demonstrated 
that methanol extract obtained from the leaves possessed 
analgesic and anti-inflammatory properties (Quintans Júnior 
et al. 2010). Owing to the presumed anti-inflammatory po-
tential of C. spicatus aqueous extract, we evaluated its abil-
ity to reduce edema, peritonitis, nociception, coagulation, 
haemorrhage and indirect haemolytic activity induced by 
B. atrox venom (BAV). 
Materials and methods 
Venom 
BAV pool was obtained from four adult specimens captured 
at Laranjal do Jari, Amapa State, Brazil (0° 38’ 12.42” S, 52° 
30’ 15.87” O). The sampling location was marked by a global 
position measuring (GPS Garmin – modelo nüvi 40). Venom 
was collected after anesthetizing the snakes with carbon 
dioxide gas. The venom samples were lyophilized and kept 
at –20 °C in the freezer until further use. The venom was di-
luted in phosphate-buffered saline (PBS) immediately prior 
to its use. 
Plant material 
Costus spicatus leaves were collected from Macapá in Amapaá 
State, Brazil, in the month of February 2012. The sampling lo-
cation (00° 2’41.821” S,  51° 5’57.2530” W) was deduced by a 
global position measuring (GPS Garmin Nüvi 40). The plant 
was identified by Prof. Wegliane Campelo da Silva Aparício, a 
taxonomist at the Department of Biology, Federal University 
of Amapá, Macapa, AP, Brazil. A voucher specimen (N°  460) 
was deposited at the Herbarium of the Federal University of 
Amapá for future reference. 
Preparation of plant extract 
Dry and pulverized leaves were extracted with distilled wa-
ter for 24 h at room temperature. Insoluble material was re-
moved by filtration. The aqueous extract (CSE) was lyophi-
lized and kept at –20 °C in a freezer until further use. Prior 
to use, the lyophilized extracts were weighed and dissolved 
in PBS. 
Animals 
Animal care was performed in accordance with the guidelines 
of the Brazilian College for Animal Experimentation. Male 
Swiss Webster mice weighing 20–25 g were used for the ex-
periments and were randomly divided into groups of five ani-
mals. The mice were kept in plastic cages with access to water 
and food ad libitum and were maintained under controlled 
temperature (18–20 °C) on a 12 h light/dark cycle. 
Groups and experimental protocols 
The experimental groups were BAV alone, C. spicatus extract 
alone (CSE), BAV+CSE in various concentrations (BAVCSE) or 
PBS alone. The venom doses used were selected from previ-
ous dose-response experiments. This initial study evaluated 
different dosages on the ability to induce measurable biolog-
ical responses. The appropriate doses are specified in each 
bioassay description below. 
Paw edema induction 
The minimum dose was defined as the lowest venom dose 
required for the formation of 30% paw edema (Rocha & 
Furtado 2007). This minimum dose was evaluated as 0.20 
mg/kg by subplantar injection of venom, in the right footpad 
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of mice. Inhibition studies were performed with CSE at sev-
eral concentrations (1.25; 2.5; 5.0; 7.5 and 10 mg CSE/kg). CSE 
and venom diluted in 50 ml PBS were injected together. Con-
trol animals received PBS (50 ml), venom (0.20 mg/kg/50 ml 
PBS) or CSE only (10 mg/kg/50 ml PBS). The progression of 
edema was evaluated with a low-pressure pachymeter (Mi-
tutoyo America Corporation, Kanagawa, Japan) 0, 0.5, 1, 2, 3 
and 4 h after injection and was expressed in mm of directly 
induced edema. 
Formalin test 
The method used was based on the protocol previously de-
scribed by Hunskaar and Hole (1987) with modifications rec-
ommended by Soares et al. (2009) and De Sousa et al. (2012). 
As a further modification, formalin used for pain induction 
was substituted by BAV at 0.20 mg/kg. Symptoms of pain 
such as intense licking and biting of the paw was recorded 
in two phases. The first period (first phase) was recorded be-
tween 0 and 5 min and the second period (second phase) 
between 20 and 30 min after the injection. The time (in sec-
onds) spent licking and biting the injected paw was taken as 
an indicator of pain intensity. The test was performed at am-
bient temperature (22–26 °C) and care was taken to exclude 
environmental disturbances (high temperature, noise and ex-
cessive movement) that might influence animal behavior. The 
animals were examined by the same observer who was re-
sponsible for all tests. Due to the number of animals, tests 
were performed during two consecutive days. CSE nocicep-
tion inhibition was evaluated at five doses (1.25; 2.5; 5.0; 7.5 
and 10mg/kg). Accordingly, CSE and BAV (0.20 mg/kg) were 
diluted in PBS (50 μl) and each preparation was injected sub-
cutaneously into the right hind paw of five mice. Control an-
imals received PBS (50 μl), venom (0.20 mg/kg/50 μl PBS) or 
CSE only (10 mg/kg/50 μl PBS). Mice were then placed un-
der glass funnel individually with mirrors around them to fa-
cilitate observation. 
Peritonitis induced by B. atrox venom 
Peritonitis assays were performed as previously described 
by Souza and Ferreira (1985) and Souza (2006). The optimal 
venom dose required to induce cellular migration without 
causing significant local haemorrhage was 0.20 mg/kg. In the 
inhibition assays, mixtures of BAV (0.20 mg/kg) and CSE (1.25; 
2.5; 5.0; 7.5 and 10 mg/kg) in PBS (50 μl) were administered 
intraperitoneally. Control animals received PBS (50 μl), venom 
(0.20 mg/ kg/50 μl PBS) or CSE (10 mg/kg/50 μl PBS) by in-
traperitoneal route. After 4 h, the animals were euthanized in 
a CO2 chamber and the peritoneal exudates were collected 
with a plastic Pasteur pipette by abdominal laparoscopy. To 
facilitate the collection, all the animals received an injection 
of 2.0 ml of heparinized PBS (1/1000 ml de PBS), and their 
abdomens were massaged to recover all leukocytes present. 
The peritoneal wash samples were diluted in Türk’s solution 
(1:20), and the cells were counted in a Neubauer chamber. 
The results were expressed as the total number of cells per 
peritoneal cavity. 
Coagulant activity 
The minimum coagulant dose, defined as the amount of 
venom that causes clotting of 200 ml human plasma in 60 s 
was 20 μg (Theakston & Reid 1983). For the inhibition tests, 
several doses of CSE (26; 52; 104; 208; 416 μg) and BAV (20 
μg) diluted in PBS (50 μl) were added immediately to citrated 
human plasma (200 μl) maintained at 37 °C. Clotting times 
were recorded. In control assays, PBS (50 μl), BAV (20 μg/50 
μl PBS) and CSE (416 mg/50 μl PBS) were added to citrated 
human plasma. 
Haemorrhagic activity 
Haemorrhage was induced by intradermal injections per-
formed on the back of mice. After 2 h, the animals were eu-
thanized in a CO2 chamber. The skin near the injection site 
was removed and haemorrhagic halo formed was measured 
in millimeters (mm) according to the method of Kondo et al. 
(1960). The diameters of the haemorrhage spot where the av-
erage of the longest diameter of the spot and the diameter 
perpendicular to the first measurement. The dose of venom 
inducing a 10mm haemorrhagic spot was 0.20 mg/kg. In the 
inhibition assays, mixtures of BAV (0.20 mg/kg) and CSE at 
five concentrations (1.25; 2.5; 5.0; 7.5 and 10 mg/kg) were 
mixed in PBS (50 μl) and were injected intradermally. Control 
animals received PBS (50 μl), venom (0.20 mg/kg/50 μl PBS) 
or CSE (10 mg/kg/50 μl PBS). 
Indirect haemolytic method 
PLA2 activity was determined by an indirect haemolytic 
method using agarose, Tris (20 mm), CaCl2 and egg yolk gels 
as substrate (Gutiérrez et al. 1988). The amount of BAV that 
produced a 10mm halo was 20 mg. Mixtures of BAV (20 μg) 
and CSE (50 μl) at five concentrations (26; 52; 104; 208 or 
416 mg/25 μl PBS) were applied at the center of the dish. Af-
ter incubation at 37 °C for 12 h, the PLA2 activity was evalu-
ated measuring the diameter of the translucent halo formed. 
PBS (50 μl), venom (20 mg/50 μl PBS) or CSE (416 mg/50 μl 
PBS) were used as controls. Measurements were recorded in 
triplicates. 
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Statistical analysis 
The results are presented as the mean ± SEM. Differences 
among groups were analyzed by one-way analysis of vari-
ance (ANOVA) followed by Tukey–Kramer test. The differ-
ences were considered to be significant when the associated 
probability of a null hypothesis (p values) were less than 5% 
(p < 0.05). 
Results 
Application of venom-induced edema and the size of the 
edema measuring the effect of CSE at time 0; 0.5; 1; 2; 3 and 
4 h after injection is reported in Table 1. CSE significantly re-
duced edema at all concentrations tested (1.25; 2.5; 5.0; 7.5 
and 10 mg/kg/25 μl PBS) when compared with BAV alone. 
In the nociception assay, the time spent licking and biting 
over fixed periods of time after subcutaneous injection of 
0.20 mg/kg BAV into the right hind paw was recorded as an 
indicator of pain. In this assay, CSE demonstrated the anal-
gesic effect on the first (0–5 min) and second phases (20–
30 min) of BAV-induced pain (Figure 1). These phases cor-
respond to neurogenic and inflammatory pain, respectively. 
In the first phase (Figure 1A), CSE significantly reduced neu-
rogenic pain at all concentrations when compared with the 
BAV group. The analgesic effect was stronger at higher con-
centration of CSE. In the second phase (Figure 1B), all doses 
of CSE significantly neutralized inflammatory pain compared 
with the animals treated with BAV alone. However, in this 
phase, lower concentrations of CSE exhibited slightly higher 
analgesic potential. 
The influx of leukocytes was analyzed by counting the 
cells in the peritoneal wash (Figure 2). CSE significantly 
decreased the number of leukocytes at the three lowest con-
centrations, which indicated an effect of CSE on the migration 
of inflammatory cells induced by venom administration. In vi-
tro studies carried out with human plasma demonstrated that 
CSE concentrations used in the present study did not inhibit 
venom coagulant activity (Figure 3). CSE effect on haemor-
rhagic activity induced by BAV was also tested. As observed 
in Figure 4, CSE did not significantly inhibit BAV-induced 
haemorrhage. Lastly, it was also demonstrated that CSE did 
not inhibit the PLA2 activity of BAV, as shown in Figure 5. 
Discussion 
The main clinical effects of Bothrops envenoming are lo-
cal tissue damage (myonecrosis, haemorrhage and edema), 
life-threatening bleeding originating from blood coagula-
tion disorders and shock (Gutiérrez 1995; Warrell 2004). In 
the present study, BAV was used to induce edema, peritoni-
tis, nociception, coagulation, haemorrhage and indirect hae-
molytic activity, and we evaluated whether or not the aque-
ous extract obtained from the leaves of C. spicatus Swartz 
could quench the effects of the venom. Venom toxicity is due 
to its proteins content. Those are mainly metalloproteinases, 
lectins, serino-proteinases, bradykinin-potentiating peptides 
and PLA2 (Guércio et al. 2006; Neiva et al. 2009). 
Quintans Júnior et al. (2010) evaluated the antinocicep-
tive and anti-inflammatory effects of the methanol extract 
obtained from the leaves of C. spicatus Swartz (MECs) on 
acetic acid-induced writhing, formalin, hotplate and carra-
geenan-induced edema tests in rodents. Our studies in mice 
showed that BAV-induced paw edema immediately after ad-
ministration and that the edema gradually decreased >4 h. 
This envenomation kinetics corroborates those from previous 
Table 1. Effect of CSE on the edema induced by B. atrox venom.
Entry  Treatment  0 h  0.5 h  1 h  2 h  3 h  4 h
1  PBS  1.8 ± 0.01  2.1 ± 0.01  2.0 ± 0.01  1.9 ± 0.01  1.9 ± 0.01  1.9 ± 0.01
2  BAV  1.88 ± 0.02  2.94 ± 0.02  2.59 ± 0.04  2.44 ± 0.03  2.38 ± 0.04  2.38 ± 0.04
3  CSE  1.91 ± 0.01  2.35 ± 0.01  2.06 ± 0.02  1.97 ± 0.02  1.97 ± 0.02  1.97 ± 0.02
4  BAVCSE 1:6  1.94 ± 0.01  2.97 ± 0.001*  2.37 ± 0.07**  2.32 ± 0.07*  2.15 ± 0.04***  2.09 ± 0.03***
5  BAVCSE 1:12  1.94 ± 0.01  2.98 ± 0.03*  2.33 ± 0.02***  2.23 ± 0.03**  2.18 ± 0.01**  2.14 ± 0.0***
6  BAVCSE 1:25  1.90 ± 0.01  2.97 ± 0.01*  2.39 ± 0.02*  2.28 ± 0.01*  2.24 ± 0.01*  2.17 ± 0.01***
7  BAVCSE 1:37  1.88 ± 0.02  2.95 ± 0.01*  2.37 ± 0.02**  2.26 ± 0.03*  2.18 ± 0.03***  2.11 ± 0.02***
8  BAVCSE 1:50  1.92 ± 0.01  2.97 ± 0.01*  2.44 ± 0.01*  2.37 ± 0.01*  2.30 ± 0.01*  2.21 ± 0.01**
4.  BAVCSE 1:6 (BAV + 1.25 mg CSE/kg/25 μl PBS); 5. BAVCSE 1:12 (BAV + 2.5 mg CSE/kg/25 μl PBS); 6. BAVCSE 1:25 (BAV + 5.0 mg CSE/kg/25 μl 
PBS); 7. BAVCSE 1:37 (BAV + 7.5 mg CSE/kg/25 μl PBS); 8. BAVCSE 1:50 (BAV + 10mg CSE/kg/25 μl PBS). The results are presented as the mean ± 
SEM on three animals. CSEtreated groups and BAV group were compared by one-way analysis of variance (ANOVA), followed by Tukey–Kramer 
test. Differences with an associated probability (p values) of less than 5% were considered significant.
* p < 0.05
** p < 0.01
*** p < 0.001
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studies that demonstrated the ability of Bothrops venom to 
induce edema through the action of venom constituents on 
vascular endothelial cells and inflammatory mediators (Bar-
bosa et al. 2008). Interestingly, we found that CSE diminished 
the edematogenic effect of BAV at all tested doses and that 
the effect lasted for 4 h. CSE also produced a significant in-
hibitory effect on the migration of inflammatory cells after 
the venom had been injected. The effect was stronger at 
the lowest concentrations tested. Many studies suggest that 
presence of glucan polysaccharides may act on the reticulo-
endothelial system, through phagocytosis stimulation, and 
can also induce vascular reactions, affecting the capillary per-
meability of the vessels (Whistler et al. 1976). Interestingly, 
glucans have been isolated from C. spicatus by da Silva and 
Parente (2003). Quintans Júnior et al. (2010) reported that 
the first phase of the edematous response was significantly 
Figure 1. Effect of CSE on the first (panel A) and the second phase (panel B) of BAV-induced nociception in mice. BAVCSE 1:6: BAV + 1.25 mg CSE/
kg/50 μl PBS; BAVCSE 1:12: BAV + 2.5 mg CSE/kg/50 μl PBS; BAVCSE 1:25: BAV + 5.0 mg CSE/kg/50 μl PBS; BAVCSE 1:37: BAV + 7.5 mg CSE/kg/50 
μl PBS; BAVCSE 1:50: BAV + 10mg CSE/kg/50 μl PBS. The results are presented as mean ± SEM for five animals. Differences between BAVCSE groups 
and BAV group were analyzed by one-way analysis of variance (ANOVA), followed by the Tukey–Kramer test. Differences with an associated proba-
bility (p values) of less than 5% (p < 0.05) were considered significant. 
*p < 0.05; **p < 0.01; ***p < 0.001.
Figure 2. Peritonitis induced by B. atrox venom and treated with CSE. 
BAVCSE 1:6: BAV + 1.25 mg CSE/kg/50 μl PBS; BAVCSE 1:12: BAV + 2.5 
mg CSE/kg/50 μl PBS; BAVCSE 1:25: BAV + 5.0 mg CSE/kg/50 μl PBS; 
BAVCSE 1:37: BAV + 7.5 mg CSE/kg/50 μl PBS; BAVCSE 1:50: BAV + 10mg 
CSE/kg/50 μl PBS. The results are presented as the mean ± SEM for five 
animals. Differences between BAVCSE groups and BAV group were an-
alyzed by one-way analysis of variance (ANOVA), followed by Tukey–
Kramer test. Differences with an associated probability (p values) of less 
than 5% (p < 0.05) were considered significant. *p < 0.05;
**p < 0.01.
Figure 3. CSE effect on B. atrox venom coagulant activity. BAV: 20 mg/50 
μl PBS. BAVCSE 1:1: BAV + 26 mg CSE/50 μl PBS; BAVCSE 1:2: BAV + 52 
mg CSE/50 μl PBS; BAVCSE 1:5: BAV + 104 mg CSE/ 50 μl PBS; BAVCSE 
1:10: BAV + 208 mg CSE/50 μl PBS; BAVCSE 1:20: BAV + 416 mg CSE/50 
μl PBS. Each experiment was carried out in triplicate. Differences between 
BAVCSE groups and BAV group were analyzed by one-way analysis of 
variance (ANOVA), followed by Tukey–Kramer test. Results did not vary 
significantly as compared with BAV (p > 0.05).
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lower in the presence of C. spicatus methanol extract (MECs) 
in rats, suggesting an inhibitory effect on the release of his-
tamine and/or serotonin. MECs also inhibited significantly the 
second and third phases of the edema, suggesting inhibition 
of 5-lipoxygenase and/or cyclooxygenase, the enzymes in-
volved in the formation of prostaglandins and leukotrienes. 
The first experimental evidence that Bothrops venoms 
induce hyperalgesia (pain hypersensitivity) was provided by 
Teixeira et al. (1994). In this study, the authors induced a 
long-lasting hyperalgesia mediated mainly by prostaglan-
din, leukotriens and PAF using B. jararaca venom. Chacur et 
al. (2001) demonstrated that bradykin is involved in hyper-
algesia induced by B. jararaca venom, which peaked 1 h af-
ter venom injection. 
The pain phenomenon takes its origin from peripheral 
sensory nerve fibres through activation of nociceptors that 
relay noxious stimuli from the periphery to the central ner-
vous system (Tortora & Grabowski 2002; Cummins et al. 
2007). The results of present study showed that BAV pro-
duced a significant nociceptive effect both at 0–5 min and 
20–30 min. The early phase may be due to direct effects on 
nociceptors, demonstrating that BAV causes an immedi-
ate sensation of pain and an increased responsiveness of 
neurons. However, more studies are needed to further in-
vestigate components and mechanism involved in the no-
ciceptive action of the snake venoms. CSE exhibited antino-
ciceptive activity in the first phase, probably by central action 
mechanism. Reports show that flavonoid-rich plant extracts 
can exhibit antinociceptive properties due to possible inter-
actions of the flavonoids with the opioid system (Ghannadi et 
al. 2005; Maleki-Dizaji et al. 2007; Quintans Júnior et al. 2010). 
In the late phase, BAV nociceptive effect can be due to an 
inflammatory response. Inflammation induced by Bothrops 
venom is characterized by a complex network of chemical 
mediators and the cellular components responsible for such 
effects. Besides the role of stored and newly generated in-
flammatory mediators, enzymes present in the venom, mainly 
PLA2 and metalloproteinases, appear to play a role in inflam-
mation and hyperalgesia induced by B. asper venom (Teixeira 
et al. 2009). Our experiments showed that CSE exhibited anti-
nociceptive activity also in the second phase as well. da Silva 
et al. (2000) isolated flavonol diglycosides tamarixetin 3-O-
neohesperidoside, kaempferide 3-O-neohesperidoside and 
the known quercetin 3-O-neohesperidoside together with six 
known flavonoids from C. spicatus leaves. Tamarixetin 3-O-
neohesperidoside and kaempferide 3-O-neohesperidoside 
showed slight inhibitory activity on nitric oxide production by 
activated macrophages. This information suggests that CES 
may act on inflammatory disorders, probably by a peripheral 
mechanism. These findings corroborate the traditional anal-
gesic and anti-inflammatory indication of the leaf infusion. 
On the other hand, our work demonstrated that CSE was not 
effective to inhibit coagulant, haemorrhagic and indirect hae-
molytic activities induced by BAV. 
Figure 5. Effects of CSE on phospholipase A2 activity of B. atrox venom. 
BAV: 20 μg/50 μl PBS. BAVCSE 1:1: BAV + 26 μg CSE/50 μl PBS; BAVCSE 
1:2: BAV + 52 μg CSE/50 μl PBS; BAVCSE 1:5: BAV + 104 μg CSE/50 ml 
PBS; BAVCSE 1:10: BAV + 208 μg BGE/50 μl PBS; BAVCSE 1:20: BAV + 
416 μg CSE/50 μl PBS. The results are presented as the mean ± SEM of 
five animals. Differences between BAVCSE groups and BAV group were 
analyzed by one-way analysis of variance (ANOVA), followed by Tukey–
Kramer test. Results in BAVCSE experiments did not vary significantly as 
compared with BAV (p > 0.05).
Figure 4. Effect of CSE on haemorrhage induced by B. atrox venom. 
BAV: 0.40 mg/50 μl PBS. BAVCSE 1:16: BAV + 3.2 mg CSE/kg/50 μl PBS; 
BAVCSE 1:32: BAV + 6.4 mg CSE/kg/50 μl PBS; BAVCSE 1:64: BAV + 12.8 
mg CSE/kg/50 μl PBS; BAVCSE 1:96: BAV + 19.2 mg CSE/kg/50 μl PBS; 
BAVCSE 1:128: BAV + 25.6 mg CSE/kg/50 μl PBS. The results are pre-
sented as the mean ± SEM of five animals. Differences between BAVCSE 
groups and BAV group were analyzed by one-way analysis of variance 
(ANOVA), followed by Tukey–Kramer test. Results in BAVCSE experiments 
did not vary significantly as compared with BAV (p > 0.05). 
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Conclusion 
This study demonstrates that C. spicatus leaf aqueous extract 
has a significant inhibitory effect on edema and migration 
of inflammatory cells, mainly at the lowest concentrations 
tested. Moreover, CSE significantly reduced BAV-induced no-
ciception in the first and second phases. CSE presumably 
acts through a central inhibitory mechanism while inhibit-
ing prostaglandin synthesis as well. The present study con-
tributes to validate the traditional use of C. spicatus leaf infu-
sion against inflammatory disorders including those caused 
by snake envenomation and accentuates the importance of 
popular knowledge in the search for alternative treatments 
to snakebite. 
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